Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 19/20 | 0.61 |
| ▸ | ITGB6 | P18564 | 10/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.61 |
| ▸ | ITGB5 | P18084 | 8/20 | 0.57 |
| ▸ | ITGB8 | P26012 | 8/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140162 | 1.00 | ITGAV (0.61) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL20141056 | 1.00 | ITGAV (0.61) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL29797277 | 0.94 | ITGB3 (0.57) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL20141097 | 0.94 | ITGB3 (0.57) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL20140538 | 0.86 | ITGAV (0.65) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL20139938 | 0.86 | ITGAV (0.65) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL20139714 | 0.86 | ITGAV (0.65) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL21294658 | 0.83 | ITGAV (0.67) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL21294650 | 0.83 | ITGAV (0.67) | ITGAVITGB3ITGB6ITGA2BITGB5 | |
| SCHEMBL20139898 | 0.83 | ITGAV (0.72) | ITGAVITGB3ITGB6ITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | claimed |
| EP-3538525-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | claimed |
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-29 | — | — | US | claimed |
| WO-2018089353-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB3, ITGB1 | ITGAV 1/4885ITGB3 2/4885ITGB6 15/4885 |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | ITGB3, ITGB1, ITGAV | ITGAV 3/4885ITGB3 1/4885ITGB6 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.